Topic: multiple sclerosis
Biogen outperformed this quarter, but analysts still worry about competition for Spinraza and an Alzheimer's candidate that hasn't yet proved out.
Roche’s blockbuster cancer trio held their ground so far this year despite biosimilar rivals in the EU, thanks to growth in the U.S. and China.
Sanofi has struggled to rev up multiple sclerosis therapy Lemtrada, but some new long-term data might help it win over doctors and patients.
Teva’s Copaxone has hung on to market share even in the face of oral competitors and generics. But Novartis aims to change that.
Roche's new five-year Ocrevus data could ratchet up the enthusiasm for the drug—and sway more payers to cover it.
Pharma may have Trump administration allies, but across the pond, Health Minister Matt Hancock has attacked, aiming his toughest remarks at Vertex.
Roche says England's health service—not Ocrevus' price—is to blame as cost watchdogs again reject the med for primary progressive MS.
Over the last few years, the multiple sclerosis field has been a hotbed for formulary management. But that’s changed a bit in 2018.
Late last month, a court refused to block copies of Acorda’s Ampyra. So the New York drugmaker took matters into its own hands.
Roche's first-half sales climbed 7% to $28.3 billion, their fastest clip in about three years, thanks to stepped-up performance from its newer drugs.